MLN3126 is an orally active and potent CCR9 antagonist. MLN3126 inhibits CCL25-induced calcium mobilization and chemotaxis of mouse primary thymocytes, wiht an IC 50 value of 6.3 nM for calcium influx.
性状
Solid
体外研究(In Vitro)
MLN3126 inhibits CCL25-induced calcium mobilization with an IC50 value of 6.3 nM in CCR9 expressing cells.MLN3126 inhibits the binding of biotinylated CCL25 to CCR9 with an IC50 of 14.2 nM. has not independently confirmed the accuracy of these methods. They are for reference only.Cell Invasion Assay
体内研究(In Vivo)
MLN3126 (2.5% w/w; p.o.) decreases colonic level of IFN-γ, largely produced by T cells.
MLN3126 (0.05, 0.25 and 1% (w/w); p.o.) has the potential activity for alleviating inflammatory bowel disease (IBD). has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model:
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years;In solvent -80°C 6 months
ClinicalTrial
参考文献
[1]. Igaki K, et al. MLN3126, an antagonist of the chemokine receptor CCR9, ameliorates inflammation in a T cell mediated mouse colitis model. Int Immunopharmacol. 2018 Jul;60:160-169.
溶解度数据
In Vitro: DMSO : 25 mg/mL (55.94 mM; ultrasonic and warming and heat to 60°C)配制储备液